<![CDATA[MRM Health NV 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=44022>Thu, 30 Apr 2026 10:47:47 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis]]>https://www.newswire.co.kr/newsRead.php?no=1026763Sun, 11 Jan 2026 10:45:00 +0900<![CDATA[MRM 헬스, 경증 내지 중등도의 궤양성 대장염에서 MH002 2b상 임상시험을 시작하기 위한 FDA IND 승인 획득]]>https://www.newswire.co.kr/newsRead.php?no=1026764Sun, 11 Jan 2026 10:45:00 +0900<![CDATA[MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline]]>https://www.newswire.co.kr/newsRead.php?no=1018070Thu, 04 Sep 2025 14:38:47 +0900<![CDATA[MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH002]]>https://www.newswire.co.kr/newsRead.php?no=987934Wed, 17 Apr 2024 09:15:00 +0900<![CDATA[MRM 헬스, MH002 임상 2a상 연구에서 주머니염에 대한 안전성 및 긍정적 효능 데이터 보고]]>https://www.newswire.co.kr/newsRead.php?no=987936Wed, 17 Apr 2024 09:15:00 +0900<![CDATA[MRM 헬스, 경증-중등도 궤양성 대장염 환자 대상 MH002의 2a상 임상시험에서 긍정적인 톱라인 결과 발표]]>https://www.newswire.co.kr/newsRead.php?no=974871Thu, 21 Sep 2023 16:40:00 +0900<![CDATA[MRM Health Reports Positive Topline Results from Phase 2a Clinical Study with MH002 in Mild-to-Moderate Ulcerative Colitis]]>https://www.newswire.co.kr/newsRead.php?no=974755Wed, 20 Sep 2023 16:48:22 +0900